Prospects in First-Line and Maintenance Settings
Joshua K. Sabari, MD, evaluates the potential of ifinatamab deruxtecan in combination with atezolizumab, with or without platinum-based chemotherapy, as first-line induction or maintenance therapy in ES-SCLC, emphasizing that statistically significant end points such as improved PFS and OS would be essential for clinical application in this patient population.
Video content above is prompted by the following:
Given the currently available data on ifinatamab deruxtecan, please evaluate its potential in combination with atezolizumab with or without platinum-based chemotherapy as first-line induction or maintenance therapy in ES-SCLC.
- What would you consider to be statistically significant end points with dual or triple therapy to warrant clinical application in this patient population?
Recent Videos
Related Content
